Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy



Status:Completed
Healthy:No
Age Range:18 - Any
Updated:10/6/2018
Start Date:September 2015
End Date:July 2018

Use our guide to learn which trials are right for you!

The purpose of this study is to assess safety and efficacy of treatment with pregabalin in
patients with idiopathic small fiber neuropathy proven by skin biopsy.This is an enriched
enrollment randomized withdrawal study that comprises 4 phases: a screening and selection
phase, a washout period from previous pain medication for enriched enrollment, an 8 week
single blind pregabalin treatment phase; and a 4 week randomized withdrawal phase.

Patients who show any increase in their pain intensity score during the washout phase will be
eligible for the single blind pregabalin treatment phase. Patients who respond to pregabalin,
with at least 1 point improvement in neuropathic pain from baseline at the end of the single
blind pregabalin treatment phase and meeting all other study requirements are considered
eligible for participation in the withdrawal phase. These eligible patients are randomly
assigned (1:1) to continue pregabalin or to be switched to placebo for a comparison of
pregabalin efficacy and safety. Patients who have a worsening of average pain relative to the
last week of the single blind pregabalin treatment period by more than one point and average
pain level > =4 will be considered to have a loss of therapeutic response (LTR).

Inclusion Criteria:

- Subjects with idiopathic predominate-small fiber neuropathy

- Subject must have chronic peripheral neuropathic pain for more than 3 months

- A score >3 and <8 on Pain intensity scale for pain in prior week at first visit;

- Show increase in pain intensity scores during the wash off period;

- Age older than 18 years;

Exclusion Criteria:

- Subjects with large-fiber predominant neuropathy

- Subjects with HIV infection, trigeminal neuralgia (TGN), toxic neuropathy (e.g.
chemotherapy exposure), paraneoplastic neuropathy, mono-gammopathy, inflammatory
neuropathy, celiac disease, systemic lupus, peripheral vascular disease, connective
tissue disorders, hepatitis C, Fabry disease, and diabetes;

- Subjects with uncontrolled thyroid or B12 disorders

- Subjects with Complex Regional Pain Syndrome

- Allergy to Pregabalin

- Subjects at risk of suicide or self harm

- Subjects with any clinically unstable cardiovascular, hematological, autoimmune,
endocrine, renal, hepatic, renal, respiratory, or gastrointestinal disease; epilepsy,
symptomatic peripheral vascular disease including intermittent claudication,
pernicious anemia, untreated hypothyroidism, venous insufficiency, or spinal stenosis.

- History of known analgesic, alcohol or illicit drug abuse within 12 months of first
visit;

- Pregnant females; breastfeeding females.
We found this trial at
1
site
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Phone: 410-955-5406
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials